Abstract:Refractory leukemia remains the most common therapeutic problem in clinical treatment of leukemia. The key therapy of refractory leukemia is to kill, thoroughly, the minimal residual disease and leukemia stem cells in the highly vascularized red marrow areas. In this study, two new conjugates, alendronate-polyethylene glycol (100) monostearate and folate-polyethylene glycol (100) monostearate, were synthesized to develop a multistep targeting nanostructured lipid carriers by enhancing drug transport to the high bone turnover areas adjacent to the red marrow and targeting the minimal residual disease and leukemia stem cells. This dual targeting system demonstrated a great binding affinity to hydroxyapatite, a model component of bone minerals, and higher cell uptake (in the form of carriers but not drug) and cytotoxicity in the K562 cell line, a leukemia cell line with overexpressed folate receptors, were observed in vitro compared to unmodified carriers, especially when the cells were pretreated and the receptors were up-regulated by all-trans retinoic acid. The comodel test of K562 cells and HA showed that this dual targeting system could desorb from bone surface and be taken up by leukemia cells. For the in vivo study, this dual targeting system exhibited a significant increase in plasma half-life and could specifically accumulate in the bone tissue of rats or mice after intravenous injection. Ex vivo imaging of mice femurs and confocal laser scanning microscope imaging of mice femur slices further confirmed that this dual targeting system could favorably deposit to the osteoblast-enriched areas of high bone turnover in regions of trabecular bone surrounded by red marrow. In vivo antitumor activity in K562/BALB/c-nu leukemia mice showed that the treatment of this dual targeting system significantly reduced the white blood cell (WBC) number in peripheral blood and bone marrow to the normal level. In conclusion, this dual targeting system could precisely target to the regions where the minimal residual disease and leukemia stem cells are located and then be specifically uptaken in large amounts, which is a valuable target for refractory leukemia therapy.

Targeted therapy for leukemia based on nanomaterials

Nano-drug Delivery System for the Treatment of Acute Myelogenous Leukemia.

Advances of Nanoparticles for Leukemia Treatment

Recent Advances in Material Technology for Leukemia Treatments

Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review)

Advanced Nanotherapeutics Inspired by the Abnormal Microenvironment of Leukemia

Application of iron oxide nanoparticles in the diagnosis and treatment of leukemia

Research Advances in Nanomedicine, Immunotherapy, and Combination Therapy for Leukemia.

Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia

Patient-Specific Nanoparticle Targeting in Human Leukemia Blood

Noble metal nanomaterials for the diagnosis and treatment of hematological malignancies

Advanced Nanoparticles That Can Target Therapy and Reverse Drug Resistance May Be the Dawn of Leukemia Treatment: A Bibliometrics Study

Nanozymes: a new approach for leukemia therapy

Research progress of nanomaterial drug delivery in tumor targeted therapy

Nanoparticles—Emerging Potential for Managing Leukemia and Lymphoma

[Basic Research on Therapy of Leukemia with Nanoparticles Drug Delivery System Modified by Transferrin Receptor Monoclonal Antibody].

Research Progress of Targeted Nanomaterials on Cancer Diagnose and Therapy

Multistep Targeted Nano Drug Delivery System Aiming at Leukemic Stem Cells and Minimal Residual Disease.

Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

Recent advance in phytonanomedicine and mineral nanomedicine delivery system of the treatment for acute myeloid leukemia

Current Progress in Cancer Treatment Using Nanomaterials